R Castan

1.5k total citations · 1 hit paper
6 papers, 1.0k citations indexed

About

R Castan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hematology. According to data from OpenAlex, R Castan has authored 6 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 2 papers in Pulmonary and Respiratory Medicine, 2 papers in Oncology and 2 papers in Hematology. Recurrent topics in R Castan's work include Hematopoietic Stem Cell Transplantation (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Cancer Treatment and Pharmacology (2 papers). R Castan is often cited by papers focused on Hematopoietic Stem Cell Transplantation (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Cancer Treatment and Pharmacology (2 papers). R Castan collaborates with scholars based in France, United States and South Africa. R Castan's co-authors include David Ferry, Radek Lakomý, Teresa Macarulla, Vladimir Moiseyenko, Carmen J. Allegra, Guy A. Van Hazel, Joe McKendrick, Eric Van Cutsem, Jana Prausová and Paul Ruff and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Transplantation and Bone Marrow Transplantation.

In The Last Decade

R Castan

6 papers receiving 1.0k citations

Hit Papers

Addition of Aflibercept to Fluorouracil, Leucovorin, and ... 2012 2026 2016 2021 2012 250 500 750

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R Castan France 4 829 392 288 200 166 6 1.0k
José María Viéitez Spain 14 1.1k 1.3× 563 1.4× 290 1.0× 219 1.1× 195 1.2× 52 1.4k
Joe McKendrick Australia 7 865 1.0× 420 1.1× 292 1.0× 219 1.1× 176 1.1× 9 1.1k
Joseph J. Schulz United States 6 1.3k 1.6× 533 1.4× 469 1.6× 264 1.3× 148 0.9× 8 1.5k
B. Nelson United States 7 795 1.0× 278 0.7× 199 0.7× 295 1.5× 92 0.6× 12 1.0k
B. Barón Belgium 17 649 0.8× 543 1.4× 155 0.5× 209 1.0× 275 1.7× 28 1.4k
Steven Blotner United States 17 598 0.7× 223 0.6× 178 0.6× 257 1.3× 175 1.1× 36 1.1k
Swantje Held Germany 17 920 1.1× 444 1.1× 278 1.0× 155 0.8× 318 1.9× 85 1.1k
Martha Donoghue United States 16 696 0.8× 400 1.0× 128 0.4× 247 1.2× 163 1.0× 27 1.2k
B. Mirtsching United States 12 1.1k 1.4× 459 1.2× 131 0.5× 182 0.9× 126 0.8× 27 1.3k
Carlos A. Garay United States 9 643 0.8× 271 0.7× 220 0.8× 93 0.5× 69 0.4× 15 860

Countries citing papers authored by R Castan

Since Specialization
Citations

This map shows the geographic impact of R Castan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R Castan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R Castan more than expected).

Fields of papers citing papers by R Castan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R Castan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R Castan. The network helps show where R Castan may publish in the future.

Co-authorship network of co-authors of R Castan

This figure shows the co-authorship network connecting the top 25 collaborators of R Castan. A scholar is included among the top collaborators of R Castan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R Castan. R Castan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

6 of 6 papers shown
1.
Cheverton, Peter, et al.. (2022). Development and validation of a predictive model to guide the use of plerixafor in pediatric population. Bone Marrow Transplantation. 57(12). 1827–1832. 2 indexed citations
2.
Alloway, Rita R., E. Steve Woodle, Daniel Abramowicz, et al.. (2019). Rabbit anti-thymocyte globulin for the prevention of acute rejection in kidney transplantation. American Journal of Transplantation. 19(8). 2252–2261. 32 indexed citations
3.
Ruff, Paul, Radek Lakomý, Jana Prausová, et al.. (2013). Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and ziv-aflibercept or placebo in mCRC patients who progressed on prior oxaliplatin treatment.. Journal of Clinical Oncology. 31(15_suppl). 3574–3574. 1 indexed citations
4.
Cutsem, Eric Van, Josep Tabernero, Radek Lakomý, et al.. (2012). Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen. Journal of Clinical Oncology. 30(28). 3499–3506. 986 indexed citations breakdown →
5.
Resnikoff, Serge, et al.. (1994). [Course of trachoma under treatment with 1% oxytetracycline ophthalmic solution].. PubMed. 17(10). 591–5. 3 indexed citations
6.
Wittreich, Johanna, Rachel I. Vogel, Thomas J. Cook, et al.. (1992). The Safety and Efficacy of Topical Norfloxacin Compared with Placebo in the Treatment of Acute, Bacterial Conjunctivitis. European Journal of Ophthalmology. 2(2). 58–66. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026